You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Optimization of Surgical and Pathological Quality Performance in Radical Surgery for Colon and Rectal Cancer: Margins and Lymph Nodes

Version: 2 ID: 17-4 nov 2016
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
Authors:
A.J. Smith, D.K. Driman, K. Spithoff, R. McLeod, A. Hunter, R.B. Rumble, B. Langer , Colon and Rectal Cancer Surgery and Pathology Expert Panel

Patient Population

Patients with curable colon and rectal cancer in whom surgical management with radical excision is undertaken. This may include selected patients with M1 disease.

This document does not apply to patients with primary cancers that are managed by polypectomy or full thickness transanal excision, patients treated for recurrent tumours, or patients undergoing surgery with palliative intent.

Research Question(s)

  1. What is the recommended technique and extent of surgical resection for curable colorectal cancer (CRC), including extent of bowel resection, extent of lymph node resection, and reporting requirements?
  2. What is the recommended approach to processing and reporting the resected specimen, including specimen marking in the operating room, as well as processing and reporting requirements in the pathology laboratory?
pdf download Summary (PDF) (360.41 Ko)
pdf download Full Report (PDF) (1.52 Mo)